Pharmacist counseling improves medication compliance of schizophrenia patients

Authors

  • Meki Pranata Pharmacy Study Program, Universitas Islam Sultan Agung, Semarang
  • Dyah Aryani Perwitasari Pharmacy Study Program, Pharmacy Faculty, Universitas Ahmad Dahlan
  • Elly Noerhidayati Medical Study Program, Universitas Islam Sultan Agung
  • Iskak Iskak Prof. Dr. Soerojo Mental Hospital Pharmacy Service, Magelang, Central Java
  • Endang Darmawan Pharmacy Study Program, Pharmacy Faculty, Universitas Ahmad Dahlan
  • Widi Angella Pharmacy Study Program, Sultan Agung Islamic University, Semarang

DOI:

https://doi.org/10.12928/pharmaciana.v15i1.25912

Keywords:

counseling, pharmacist, MARS, schizophrenic, adherence medication

Abstract

Schizophrenia is a disorder characterized by abnormal behavior, impaired thinking, disorganized speech, and a reduced ability to perceive reality. One of the key factors influencing the success of schizophrenia therapy is patient adherence. Pharmacy plays a crucial role in the treatment of schizophrenia patients. This study aimed to determine the effect of pharmacist counseling on drug adherence of schizophrenia patients from the first month to the second month. The method used in this study was a one-group pre-test and post-test design that used quasi-experimental research. The subjects of this study were schizophrenia patients in the outpatient installation of Prof.Dr.Soerojo Mental Hospital, Magelang. This study used the Medication Adherence Rating Scale (MARS) questionnaire to measure the level of adherence and drug use monitoring sheet (pill count) to monitor the amount of patient medication. The population in this study was calculated using the Lameshow formula. Data analysis was performed using the chi-square test and the Wilcoxon test. After analyzing data of 108 patients, it was found that there was a significant difference between before and after counseling conducted by pharmacists on medication adherence in schizophrenia patients, with a significance value of p <0.05. Counseling conducted by pharmacists has a good impact on patient medication adherence and monitoring the amount of medication taken. These results indicate the effect of counseling conducted by pharmacists on adherence to taking medication and the monitoring of the amount of medication taken by patients.

References

Acosta, F. J. (2012). Medication adherence in schizophrenia. World Journal of Psychiatry, 2(5), 74. https://doi.org/10.5498/wjp.v2.i5.74

Bamgbade, B. A., Barner, J. C., & Ford, K. H. (2017). Evaluating the Impact of an Anti-stigma Intervention on Pharmacy Students’ Willingness to Counsel People Living with Mental Illness. Community Mental Health Journal, 53(5), 525–533. https://doi.org/10.1007/s10597-016-0075-6

Both, C., Mechler, K., Niemeyer, L., Jennen-Steinmetz, C., Hohmann, S., Schumm, L., Dittmann, R. W., & Häge, A. (2021). Medication adherence in adolescents with psychiatric disorders: The relevance of demographic and socioeconomic factors plus parents’ assessments of their offspring’s attitudes towards treatment. Zeitschrift Fur Kinder- Und Jugendpsychiatrie Und Psychotherapie, 49(4), 295–306. https://doi.org/10.1024/1422-4917/a000813

Brain, C., Sameby, B., Allerby, K., Lindström, E., Eberhard, J., Burns, T., & Waern, M. (2014). Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: A comparison of methods for the measurement of adherence in schizophrenia. European Neuropsychopharmacology, 24(2), 215–222. https://doi.org/10.1016/j.euroneuro.2013.11.013

Çetin, N., & Aylaz, R. (2018). The effect of mindfulness-based psychoeducation on insight and medication adherence of schizophrenia patients. Archives of Psychiatric Nursing, 32(5). https://doi.org/10.1016/j.apnu.2018.04.011

El-Mallakh, P., & Findlay, J. (2015). Strategies to improve medication adherence in patients with schizophrenia: The role of support services. In Neuropsychiatric Disease and Treatment (Vol. 11, pp. 1077–1090). Dove Medical Press Ltd. https://doi.org/10.2147/NDT.S56107

Eticha, T., Teklu, A., Ali, D., Solomon, G., & Alemayehu, A. (2015). Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia. PLoS ONE, 10(3). https://doi.org/10.1371/journal.pone.0120560

Furukawa, T. A., Levine, S. Z., Tanaka, S., Goldberg, Y., Samara, M., Davis, J. M., Cipriani, A., & Leucht, S. (2015). Initial severity of schizophrenia and efficacy of antipsychotics: Participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry, 72(1). https://doi.org/10.1001/jamapsychiatry.2014.2127

Haddad, P., Brain, C., & Scott, J. (2014). Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Related Outcome Measures, 43. https://doi.org/10.2147/prom.s42735

Higashi, K., Medic, G., Littlewood, K. J., Diez, T., Granström, O., & de Hert, M. (2013). Medication adherence in schizophrenia: Factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology, 3(4), 200–218. https://doi.org/10.1177/2045125312474019

Hsieh, W. L., Yeh, S. T., Liu, W. I., Li, I. H., Lee, S. K., & Chien, W. T. (2022). Improving medication adherence in community-dwelling patients with schizophrenia through therapeutic alliance and medication attitude: a serial multiple mediation model. Patient Preference and Adherence, 16, 1017–1026. https://doi.org/10.2147/PPA.S351848

Jorquera, N., Alvarado, R., Libuy, N., & de Angel, V. (2015). Association between unmet needs and clinical status in patients with first episode of schizophrenia in Chile. Frontiers in Psychiatry, 6(APR). https://doi.org/10.3389/fpsyt.2015.00057

Julaeha, J., Athiyah, U., Yuliana, V., Ayuningtyas, J. P., & Hermansyah, A. (2020). Revisiting the intractable barriers affecting medication adherence among outpatients with schizophrenia. Current Trends in Biotechnology and Pharmacy, 14(5). https://doi.org/10.5530/ctbp.2020.4s.24

Kemenkes RI. (2019). Profil Kesehatan Indonesia 2018 [Indonesia Health Profile 2018]. http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/Data-dan-Informasi_Profil-Kesehatan-Indonesia-2018.pdf

Kim, J., Ozzoude, M., Nakajima, S., Shah, P., Caravaggio, F., Iwata, Y., de Luca, V., Graff-Guerrero, A., & Gerretsen, P. (2020). Insight and medication adherence in schizophrenia: An analysis of the CATIE trial. Neuropharmacology, 168. https://doi.org/10.1016/j.neuropharm.2019.05.011

Lee, Y., Lee, M. S., Jeong, H. G., Youn, H. C., & Kim, S. hyun. (2019). Medication adherence using electronic monitoring in severe psychiatric illness: 4 and 24 weeks after discharge. Clinical Psychopharmacology and Neuroscience, 17(2), 288–296. https://doi.org/10.9758/cpn.2019.17.2.288

Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021). Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders. BMC Psychiatry, 21(1). https://doi.org/10.1186/s12888-021-03037-0

Medic, G., Higashi, K., Littlewood, K. J., Diez, T., Granström, O., & Kahn, R. S. (2012). Dosing frequency and adherence in chronic psychiatric disease: Systematic review and meta-analysis. In Neuropsychiatric Disease and Treatment 9 (1), 119–131). Dove Medical Press Ltd. https://doi.org/10.2147/NDT.S39303

Misdrahi, D., Petit, M., Blanc, O., Bayle, F., & Llorca, P. M. (2012). The influence of therapeutic alliance and insight on medication adherence in schizophrenia. Nordic Journal of Psychiatry, 66(1). https://doi.org/10.3109/08039488.2011.598556

Mounica. Bollu, Shaik Faizan Ali, Dr. Desu Brahma Srinivasa Rao, Nallani Venkataramarao, & Dr. Nalluri. Murali Krishna M.D. (2015). Role of clinical pharmacist in promoting patient compliance through assessment of reasons for non-compliance and minimum maintenance dose titrations in schizophrenic patients. International Journal of Indian Psychology, 3(1). https://doi.org/10.25215/0301.129

Ní Dhubhlaing, C., Young, A., & Sahm, L. J. (2017). Impact of pharmacist counselling on clozapine knowledge. Schizophrenia Research and Treatment, 2017. https://doi.org/10.1155/2017/6120970

Novick, D., Montgomery, W., Treuer, T., Aguado, J., Kraemer, S., & Haro, J. M. (2015). Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: Results from a 1-year European outpatient observational study. BMC Psychiatry, 15(1). https://doi.org/10.1186/s12888-015-0560-4

O’Reilly, C. L., Bell, J. S., Kelly, P. J., & Chen, T. F. (2015). Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. Research in Social and Administrative Pharmacy, 11(3), e101–e109. https://doi.org/10.1016/j.sapharm.2013.04.006

Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017). Guidelines for the Pharmacotherapy of Schizophrenia in Adults. In Canadian Journal of Psychiatry, 62 (9),604–616). SAGE Publications Inc. https://doi.org/10.1177/0706743717720448

Ritsner, M. S., & Grinshpoon, A. (2015). Ten-year quality-of-life outcomes of patients with schizophrenia and schizoaffective disorders: The relationship with unmet needs for care. Clinical Schizophrenia and Related Psychoses, 9(3). https://doi.org/10.3371/CSRP.RIGR.030813

Rubio, J. M., Taipale, H., Tanskanen, A., Correll, C. U., Kane, J. M., & Tiihonen, J. (2021). Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study. Schizophrenia Bulletin, 47(6), 1611–1620. https://doi.org/10.1093/schbul/sbab063

Samaksha, P. B., Kishor, M., & Ramesh, M. (2022). A novel study on clinical pharmacist and psychiatrist collaborative pharmacotherapy management services among elderly population with psychiatric illness. Indian Journal of Psychiatry, 64(1), 20–24. https://doi.org/10.4103/indianjpsychiatry.indianjpsychiatry_379_21

Sendt, K. V., Tracy, D. K., & Bhattacharyya, S. (2015). A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. In Psychiatry Research (Vol. 225, Issues 1–2). https://doi.org/10.1016/j.psychres.2014.11.002

Shnayder, N. A., Novitsky, M. A., Neznanov, N. G., Limankin, O. v., Asadullin, A. R., Petrov, A. v., Dmitrenko, D. v., Narodova, E. A., Popenko, N. v., & Nasyrova, R. F. (2022). Genetic Predisposition to Schizophrenia and Depressive Disorder Comorbidity. In Genes,13(3). MDPI. https://doi.org/10.3390/genes13030457

Stentzel, U., van den Berg, N., Schulze, L. N., Schwaneberg, T., Radicke, F., Langosch, J. M., Freyberger, H. J., Hoffmann, W., & Grabe, H. J. (2018). Predictors of medication adherence among patients with severe psychiatric disorders: Findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry, 18(1). https://doi.org/10.1186/s12888-018-1737-4

Stuhec, M., Bratović, N., & Mrhar, A. (2019). Impact of clinical pharmacist’s interventions on pharmacotherapy management in elderly patients on polypharmacy with mental health problems including quality of life: A prospective non-randomized study. Scientific Reports, 9(1). https://doi.org/10.1038/s41598-019-53057-w

Takeuchi, H., Siu, C., Remington, G., Fervaha, G., Zipursky, R. B., Foussias, G., & Agid, O. (2019). Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology, 44(6), 1036–1042. https://doi.org/10.1038/s41386-018-0278-3

Tan, Y. M., Chong, C. P., & Cheah, Y. C. (2019). Impact of hospital pharmacist-led home medication review program for people with schizophrenia: A prospective study from Malaysia. Journal of Applied Pharmaceutical Science, 9(7), 034–041. https://doi.org/10.7324/JAPS.2019.90705

Tarutani, S., Kikuyama, H., Ohta, M., Kanazawa, T., Okamura, T., & Yoneda, H. (2016). Association between medication adherence and duration of outpatient treatment in patients with schizophrenia. Psychiatry Investigation, 13(4), 413–419. https://doi.org/10.4306/pi.2016.13.4.413

Tessier, A., Boyer, L., Husky, M., Baylé, F., Llorca, P. M., & Misdrahi, D. (2017). Medication adherence in schizophrenia: The role of insight, therapeutic alliance and perceived trauma associated with psychiatric care. Psychiatry Research, 257, 315–321. https://doi.org/10.1016/j.psychres.2017.07.063

Thompson, K., Kulkarni, J., & Sergejew, A. A. (2000). Reliability and validity of a new Medication Adherence Rating Scale (MARS ) for the psychoses k. In Schizophrenia Research,42. www.elsevier.com/locate/schres

Tiandini, W, & Khairina. (2020). Schizophrenia patient’s need assessment. Jurnal Psikiatri Surabaya, 9(1), 19-24

Tiihonen, J., Tanskanen, A., & Taipale, H. (2018). 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. American Journal of Psychiatry, 175(8), 765–773. https://doi.org/10.1176/appi.ajp.2018.17091001

Volk, D. W., Jenkins, A. K., Lidstone, P. A., & Lewis, D. A. (2020). Schizophrenia. In Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease: Volume 2 (pp. 653–662). Elsevier. https://doi.org/10.1016/B978-0-12-813866-3.00038-2

Yalamova, I. V. (2015). Post-discharge medication adherence in schizophrenia. Archives of Psychiatry and Psychotherapy, 17(4), 39–47. https://doi.org/10.12740/APP/60513

Yalçin, N., Ak, S., Gürel, Ş. C., & Çeliker, A. (2019). Compliance in schizophrenia spectrum disorders: The role of clinical pharmacist. International Clinical Psychopharmacology, 34(6), 298–304. https://doi.org/10.1097/YIC.0000000000000280

Yalcin, N., Celiker, A., Gurel, S. C., Ak, S., & Yazici, M. K. (2018). S54. The role of the clinical pharmacist in drug education for increasing compliance with drug therapy in the period of discharge with the diagnosis of schizophrenia spectrum disorders. Schizophrenia Bulletin, 44(suppl_1), S345–S345. https://doi.org/10.1093/schbul/sby018.841

Downloads

Published

2025-03-21

Issue

Vol. 15 No. 1 (2025): Pharmaciana

Section

Clinical and Community Pharmacy

License

Copyright (c) 2025 Meki Pranata, Dyah Aryani Perwitasari, Elly Noerhidayati, Iskak Iskak, Endang Darmawan, Widi Angella

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.